AZN vs NVS
AstraZeneca PLC and Novartis AG, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | AZN | NVS |
|---|---|---|
| Revenue | $58.7B | $54.5B |
| Net income | $10.2B | $14.0B |
| Gross margin | 81.9% | 78.8% |
| Net margin | 17.4% | 25.6% |
| Return on equity | 22.9% | 31.0% |
| Diluted EPS | $6.54 | $7.15 |
| Dividend / share | $3.13 | · |
| Payout ratio | 48.6% | · |
| Free cash flow | $11.8B | $17.6B |
| Equity | $48.7B | $46.1B |
| Net debt / equity | 0.49× | 0.37× |
| Current ratio | 0.94× | 1.12× |
| Revenue CAGR 5y | 17.2% | 2.3% |
| Profit CAGR 5y | 26.2% | 11.6% |
AZN and NVS book revenue within 15% of each other, and NVS keeps more of each dollar of revenue as profit (25.6% against 17.4%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | AZN | NVS |
|---|---|---|
| FY2025 | $58.7B | $54.5B |
| FY2024 | $54.1B | $50.3B |
| FY2023 | $45.8B | $45.4B |
| FY2022 | $44.4B | $42.2B |
| FY2021 | $37.4B | $42.8B |
| FY2020 | $26.6B | $48.7B |
| FY2019 | $24.4B | $47.5B |
| FY2018 | $22.1B | $44.8B |
| FY2017 | $22.5B | $42.4B |
| FY2016 | $23.0B | $48.5B |
Bottom line
| Fiscal year | AZN | NVS |
|---|---|---|
| FY2025 | $10.2B | $14.0B |
| FY2024 | $7.0B | $11.9B |
| FY2023 | $6.0B | $14.8B |
| FY2022 | $3.3B | $7.0B |
| FY2021 | $112.0M | $24.0B |
| FY2020 | $3.2B | $8.1B |
| FY2019 | $1.3B | $11.7B |
| FY2018 | $2.2B | $12.6B |
| FY2017 | $3.0B | $7.7B |
| FY2016 | $3.5B | $6.7B |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$4,207,000,000 | AZN |
| FY2024 | +$3,756,000,000 | AZN |
| FY2023 | +$371,000,000 | AZN |
| FY2022 | +$2,145,000,000 | AZN |
| FY2021 | −$5,364,000,000 | NVS |
| FY2020 | −$22,042,000,000 | NVS |
| FY2019 | −$23,114,000,000 | NVS |
| FY2018 | −$22,743,000,000 | NVS |
| FY2017 | −$19,916,000,000 | NVS |
| FY2016 | −$25,516,000,000 | NVS |
The higher-revenue side has changed between AZN and NVS over this period. The gap has narrowed since the earliest year compared.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −8.2 pp | NVS |
| FY2024 | −10.7 pp | NVS |
| FY2023 | −19.7 pp | NVS |
| FY2022 | −9.1 pp | NVS |
| FY2021 | −55.8 pp | NVS |
| FY2020 | −4.8 pp | NVS |
| FY2019 | −19.7 pp | NVS |
| FY2018 | −18.9 pp | NVS |
| FY2017 | −5.4 pp | NVS |
| FY2016 | +1.0 pp | AZN |
The higher net margin has changed hands between AZN and NVS over this period.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NVS's net margin has been more volatile than AZN's over the 10 comparable fiscal years — 11.6 percentage points of standard deviation against 4.8.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between AZN and NVS over these 10 fiscal years — AZN led in 1 and NVS in 9.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NVS's return on equity has been more volatile than AZN's over the 10 comparable fiscal years — 9.6 percentage points of standard deviation against 6.8.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between AZN and NVS over these 10 fiscal years — AZN led in 3 and NVS in 7.
10 of 11 comparable fiscal years — a year missing data on either side is not counted.